Targeting optimal HbA1c level in type 2 diabetes using appropriate blood glucose lowering medicine

Contributor
He Ako Hiringa
3 May 2021
HAH Applied

This Quality Improvement Activity enables you to review the glycaemic management of your type 2 diabetes patients and identify those who may benefit from initiation or intensification of blood glucose lowering medicines.

Good glycaemic control has a clear benefit on microvascular outcomes and if started early enough, on long-term macrovascular outcomes of coronary artery disease, stroke and peripheral vascular disease.

This is a Measuring and Improving Outcomes (MIO) activity that meets RNZCGP CPD requirements.

Click here to open the document, then download it to your computer before you complete the CME section.